Drug intelligence / Profile preview

HKUB-005

Development stage: Preclinical
Lead developer: Hong Kong Universal Biologicals
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

HKUB-005 is a preclinical-stage viral vector vaccine candidate developed by Hong Kong Universal Biologicals (HKU Bio). It is designed to provide protection against H5N1 avian influenza and other emerging infectious diseases. The vaccine is built upon the company's proprietary "Innovative Viral Vector Platform," which is engineered to induce robust and targeted immune responses against H5N1 antigens. By utilizing viral vector technology, HKUB-005 aims to address the global health threat posed by highly pathogenic avian influenza strains that could lead to potential pandemics.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on HKUB-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HKUB-005.

Explore the full profile